Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 492.13% and ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Eighty percent of doctors in a Medscape survey answered no when asked, “Is enough known about obesity meds’ risk to ...

Also, Amgen’s weight loss drug had little chance to gain market share because of Lilly’s and Novo’s dominance. Data shows ...

a gastroenterologist who runs a weight loss clinic in Cary, North Carolina, tells TODAY.com. GLP-1 drugs — which include Ozempic and its sister drug Wegovy, as well as Mounjaro and Zepbound ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

It is more common among people who have obesity. The new approval could open the door for Zepbound coverage by Medicare and ...

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

Amazon may be known for its retail and tech chops, but the company has also built a strong operation in the healthcare realm ...

The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe ...

Among the many newcomers to the business of weight-loss drugs is Hims & Hers, an American e-pharmacy better known for hawking ...